Your browser doesn't support javascript.
loading
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
Kumar, J; Fraser, F W; Riley, C; Ahmed, N; McCulloch, D R; Ward, A C.
Affiliation
  • Kumar J; 1] School of Medicine, Deakin University, Geelong, Victoria 3216, Australia [2] Strategic Research Centre in Molecular and Medical Research, Deakin University, Geelong, Victoria 3216, Australia.
  • Fraser FW; 1] School of Medicine, Deakin University, Geelong, Victoria 3216, Australia [2] Strategic Research Centre in Molecular and Medical Research, Deakin University, Geelong, Victoria 3216, Australia.
  • Riley C; Women's Cancer Research Centre, Royal Women's Hospital, Parkville, Victoria 3052, Australia.
  • Ahmed N; 1] Women's Cancer Research Centre, Royal Women's Hospital, Parkville, Victoria 3052, Australia [2] Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria 3052, Australia.
  • McCulloch DR; 1] School of Medicine, Deakin University, Geelong, Victoria 3216, Australia [2] Strategic Research Centre in Molecular and Medical Research, Deakin University, Geelong, Victoria 3216, Australia.
  • Ward AC; 1] School of Medicine, Deakin University, Geelong, Victoria 3216, Australia [2] Strategic Research Centre in Molecular and Medical Research, Deakin University, Geelong, Victoria 3216, Australia.
Br J Cancer ; 110(1): 133-45, 2014 Jan 07.
Article in En | MEDLINE | ID: mdl-24220695
ABSTRACT

BACKGROUND:

Ovarian cancer remains a major cause of cancer mortality in women, with only limited understanding of disease aetiology at the molecular level. Granulocyte colony-stimulating factor (G-CSF) is a key regulator of both normal and emergency haematopoiesis, and is used clinically to aid haematopoietic recovery following ablative therapies for a variety of solid tumours including ovarian cancer.

METHODS:

The expression of G-CSF and its receptor, G-CSFR, was examined in primary ovarian cancer samples and a panel of ovarian cancer cell lines, and the effects of G-CSF treatment on proliferation, migration and survival were determined.

RESULTS:

G-CSFR was predominantly expressed in high-grade serous ovarian epithelial tumour samples and a subset of ovarian cancer cell lines. Stimulation of G-CSFR-expressing ovarian epithelial cancer cells with G-CSF led to increased migration and survival, including against chemotherapy-induced apoptosis. The effects of G-CSF were mediated by signalling via the downstream JAK2/STAT3 pathway.

CONCLUSION:

This study suggests that G-CSF has the potential to impact on ovarian cancer pathogenesis, and that G-CSFR expression status should be considered in determining appropriate therapy.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Receptors, Colony-Stimulating Factor / Neoplasms, Glandular and Epithelial / STAT3 Transcription Factor / Janus Kinase 2 Limits: Female / Humans Language: En Journal: Br J Cancer Year: 2014 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Receptors, Colony-Stimulating Factor / Neoplasms, Glandular and Epithelial / STAT3 Transcription Factor / Janus Kinase 2 Limits: Female / Humans Language: En Journal: Br J Cancer Year: 2014 Document type: Article Affiliation country: Australia